TARGETING THE PAM50 HER2-ENRICHED PHENOTYPE WITH ENZALUTAMIDE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER - ARIANNA

SOLTI0 个研究点目标入组 40 人开始时间: 2019年9月4日最近更新: 2023年10月23日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: SOLTI
入组人数: 40

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•* Written informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures.
•* Subjects with progression on or following at least 1 prior standard of care systemic anti-cancer therapy.
•* Female and male patients.
•* Performance status of 0-2.
•* Age =18 years.
•* Pre/peri-menopausal and post-menopausal women. Post-menopausal status is defined either by:
•-Prior bilateral oophorectomy or
•-Age =60 or
•-Age < 60 and amenorrhea for = 12 months (in the absence of chemotherapy, tamoxifen, toremifen, or ovarian suppression) and FSH and estradiol in the post-menopausal range per local standards.
•-If a patient is taking tamoxifen or toremifene and is aged < 60, then FSH and plasma estradiol levels should be in post-menopausal range per local values.
•-For women with therapy-induced amenorrhea, measurement of FSH and/or estradiol are needed to ensure menopausal status.
•* Life expectancy = 12 weeks.
•* Locally advanced or metastatic BC not amenable to curative intent.
•* Histologically confirmed HR-positive/HER2-negative disease based on the most recent biopsy before signing the informed consent.
•-HER2 negativity is defined as either of the following by local laboratory assessment: IHC 0, IHC 1+ or IHC2+/in situ hybridisation (ISH/FISH) negative as per American Society of Clinical Oncology (ASCO)-College of American Pathologists Guideline (CAP) guideline(73).
•-ER and/or PR positivity are defined as >1% of cells expressing HR via IHC analysis as per ASCO-CAP guideline (74)
•* Patients must have a site of disease amenable to safely perform a biopsy, as per Investigator’s assessment, and be a candidate for tumor biopsy according to the treating institution’s guidelines.
•* Possibility of performing a biopsy prior to the start of treatment and its repetition after 2 weeks (14-21 days) on the same location. It will be provided formalin-fixed paraffin-embedded (FFPE) tumor block. The tumor tissue should be of good quality based on total and viable tumor content and must be evaluated centrally for PAM50 analysis prior to enrollment. Patients whose tumor tissue is not evaluable for central testing are not eligible. It is recommended to send the biopsy directly to the central lab after confirming the existence of a tumor, so as not to delay the inclusion, without the need to carry out IHC studies in the same.
•-Acceptable samples include core needle biopsies for deep tumor tissue or excisional, incisional, punch, or forceps biopsies for cutaneous, subcutaneous, or mucosal lesions or biopsies from bone metastases.
•-Fine needle aspiration, brushing, cell pellet from pleural effusion and lavage samples are not acceptable.
•* Patient must be willing to provide biopsy prior to the start of treatment and its repetition after 2 weeks (14-21 days) on the same location.
•* The following subtypes identified in the pre-treatment tumor biopsy, as assessed by PAM50 assay at the Central Laboratory:
•-HER2-E (Cohort A)
•-Luminal A and Luminal B (Cohort B).
•* No more than 4 prior lines of chemotherapy regimens for recurrent, locally advanced or metastatic breast cancer.
•* Endocrine resistant disease, defined as the presence of disease recurrence while receiving adjuvant endocrine therapy for early stage breast cancer or disease progression of locally advanced/metastatic BC under ongoing endocrine therapy. There is no limit of previous received hormonal agents.
•* Measurable and non-measurable (but evaluable) dise

排除标准

•* History of current or previously treated CNS metastases or leptomeningeal disease. Testing for CNS metastasis is not mandatory.
•* History of seizure or any condition that may predispose to seizure.
•* Clinically significant cardiovascular disease within 6 months prior to enrolment defined as:
•-Myocardial infarction.
•-Inadequately controlled angina or serious cardiac arrhythmia not controlled by adequate medication.
•-Congestive heart failure (CHF) New York Health Association (NYHA) Class = II.
•-History of clinically significant ventricular arrhythmias (eg, ventricular tachycardia, ventricular fibrillation, torsade de pointes).
•- History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place.
•-Hypotension as indicated by systolic blood pressure < 86 millimeters of mercury (mmHg) on 2 consecutive measurements at the screening visit.
•-Bradycardia as indicated by a heart rate of < 50 beats per minute on the screening electrocardiogram (ECG) recording.
•-Uncontrolled hypertension as indicated by systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg on 2 consecutive measurements at the screening visit.
•* Inability to swallow tablets, extensive reduction surgery of the stomach or small bowel or any active gastrointestinal disorder which may impair the absorption of the trial treatment (e.g. active peptic ulcer disease; uncontrolled celiac disease).
•*Major surgical procedure within 4 weeks prior to allocation or anticipation of the need for major surgery during the course of study treatment.
•*Use of medications that could reduce seizure threshold or concomitant treatment with potent CYP3A4 inducers.
•*Treatment with warfarin and coumarin-like anticoagulants. Prophylactic use of low molecular weight heparin (LMWH) is allowed.
•*Fructose intolerance.
•* Treatment with any anticancer commercially available or investigational drug within 14 days prior to commencing trial treatment.
•*Hypersensitivity reaction to the active pharmaceutical ingredient or any of the capsule components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene.
•*Current severe disease, infection, or systemic condition that renders the patient inappropriate for enrollment in the opinion of the investigator.
•*Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
•*Has a known history of Human Immunodeficiency Virus (HIV).
•*Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
•*Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
•*Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of enzalutamide.

研究者

发起方

SOLTI

相似试验

进行中（未招募）

1 期

Assesment of response predictor genes in patients with initial breast cancer HER2+ to the lapatinib and trastuzumab treatment combination before surgery.ntreated invasive breast carcinoma eligible for primary definitive surgery (Stage I-IIIA)MedDRA version: 14.1Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2013-001036-22-ESSOLTI

招募中

不适用

Plasma HER2 amplification in cell-free DNA to detect resistance to chemotherapy with anti-HER2 antibodies in gastric cancerGastric Cancer

JPRN-UMIN000036867Kyushu Study group of Clinical Cancer84

招募中

不适用

A study for assessment of HER2 status using Gene-Protein Assay (GPA) in metastatic colorectal cancercolorectal cancer

JPRN-UMIN000039751ational Cancer Center150

招募中

2 期

Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)HER2 Enriched Subtype Breast Cancer, Herzuma, PAM50 Study

NCT04817540Gangnam Severance Hospital59

招募中

1 期

Study of Biological Effect in Tumor Samples from Clinical Trial Patients Treated with Ds8201Patients diagnosed with advanced or metastatic cancer treated with Trastuzumab Deruxtecan in the context of a clinical trial/expanded access/ compassionate use or standard treatment, irrespective of histologic type.

CTIS2023-508830-33-00Solti Group180